Y-Intercept (HK)’s Supernus Pharmaceuticals SUPN Stock Holding History

Y-Intercept (HK)’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	38,494 +18,258	+90%	+$877K	0.04%	763
2026 Q1	$1.05M	Buy	20,236 +3,096	+18%	+$158K	0.02%	1014
2025 Q4	$852K	Buy	+17,140	New	+$833K	0.02%	1050
2023 Q4	–	Sell	-16,131	Closed	-$445K	–	1626
2023 Q3	$445K	Buy	+16,131	New	+$491K	0.04%	608

Other funds holding SUPN

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

CNAM

Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Y-Intercept (HK)'s SUPN Position: Q2 2026 in Review

Y-Intercept (HK) increased its Supernus Pharmaceuticals (SUPN) stake by 90% in Q2 2026, buying an estimated $877K and bringing the position to 38,494 shares worth $1.79M. The position accounts for 0.04% of the portfolio, ranked #763.

Y-Intercept (HK) first reported a position in SUPN in Q3 2023 and has held it in 4 quarters since. 44 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Y-Intercept (HK) held 38,494 shares of Supernus Pharmaceuticals worth $1.79M as of Q2 2026.
Y-Intercept (HK) bought 18,258 Supernus Pharmaceuticals shares in Q2 2026, an estimated $877K.
Supernus Pharmaceuticals made up 0.04% of Y-Intercept (HK)'s portfolio in Q2 2026, its #763 holding.
Y-Intercept (HK) first reported a position in Supernus Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
44 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.